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PURPOSE. X-linked retinoschisis (XLRS) is an early-onset retinal
disease caused by mutations in retinoschisin (RS1), a multisub-
unit, extracellular protein implicated in retinal cell adhesion.
Delivery of the normal RS1 gene to photoreceptors of retinos-
chisin-deficient mice results in prolonged protein expression
and rescue of retinal structure and function. However, most
persons with XLRS harbor a missense mutation in the RS1 gene
leading to expression of a nonfunctional protein. The purpose
of this study was to examine the effect that coexpression of
wild-type RS1 with disease-causing mutants has on RS1 expres-
sion, oligomerization, and secretion to further evaluate gene
therapy as a possible treatment for XLRS.
METHODS. RS1 mutants (C59S, D158N, C142W, C142S, T185K,
R141H, R141G) were individually expressed or coexpressed
with myc-tagged wild-type RS1 (myc-RS1) in EBNA293 cells.
Protein expression, secretion, and subunit assembly of wild-
type and mutant RS1 were analyzed by Western blotting and
coimmunoprecipitation. Immunofluorescence was used to ex-
amine the cellular distribution of RS1.
RESULTS. Myc-RS1 was identical to untagged, wild-type RS1 with
respect to cellular localization, disulfide-linked octamer forma-
tion, and secretion. In coexpression studies, myc-RS1 assem-
bled into a disulfide-linked octameric complex and was se-
creted from cells independent of all disease-linked RS1 mutants
studied except the R141H mutant.
CONCLUSIONS. When wild-type RS1 is expressed in the same
cells as disease-causing mutants, the wild-type protein under-
goes protein folding, subunit assembly, and secretion indepen-
dent of all disease-causing RS1 mutants studied except R141H.
These studies suggest that gene therapy may be an effective
treatment for most persons with XLRS. (Invest Ophthalmol Vis
Sci. 2007;48:2491–2497) DOI:10.1167/iovs.06-1465
X-linked retinoschisis (XLRS) is a leading cause of early-onset macular degeneration in males. Affected persons
typically display cystic streaks projecting from the parafoveal
region of the retina, a decrease in visual acuity, and a reduction
in the b-wave amplitude of the full-field electroretinogram
(ERG).1,2 Optical coherence tomography (OCT) further reveals
a splitting of the outer plexiform and adjacent retinal layers.3,4
During the course of the disease, retinal detachment, vitreal
hemorrhage, and neovascular glaucoma can arise as secondary
complications, leading to a poor visual outcome. Female carri-
ers are clinically unaffected.
The RS1 gene associated with XLRS encodes a 224-amino
acid protein known as retinoschisin, or RS1,5 which is ex-
pressed and secreted primarily from photoreceptor cells.6 – 8
Retinoschisin consists of a 23-amino acid N-terminal signal
or leader peptide, a 39-amino acid Rs1 domain, a 157-amino
acid discoidin domain, and a 5-amino acid C-terminal seg-
ment.5,9,10 The signal peptide directs the nascent polypep-
tide chain across the endoplasmic reticulum (ER) mem-
brane. A signal peptidase in the lumen of the ER removes the
signal peptide, enabling the processed polypeptide to as-
semble into a disulfide-linked octameric complex for secre-
tion from cells.9 Disulfide-linked octamer formation is me-
diated by two cysteine residues, one in the Rs1 domain
(C59) and one in the C-terminal segment (C223). The dis-
coidin domain is the main structural feature of retinoschisin.
Discoidin domains, first discovered in discoidin proteins of
the slime mold Dictyostelium discoideum, have been found
in a variety of extracellular and cell surface membrane pro-
teins, including blood coagulation factors 5 and 8, milk fat
globule protein, neuropilins 1 and 2, neurexin IV, and dis-
coidin domain receptor protein tyrosine kinases.11,12 The
function of discoidin domains is not understood, though
they have been implicated in cell adhesion, signaling, and
development.
To date, more than 130 different mutations in the RS1
gene have been associated with XLRS.13 The effects of a
number of disease-causing missense mutations on retino-
schisin expression, structure, subunit assembly, and secre-
tion have been investigated in culture cells.9,10,14,15 Mis-
sense mutations in the signal peptide prevent translocation
of the polypeptide across the ER membrane, resulting in
rapid protein degradation. Disease-causing mutations in the
Rs1 domain and C-terminal segment prevent the normal
assembly of retinoschisin into a homo-octamer. Most muta-
tions in the discoidin domain cause protein misfolding and
retention in the cell by the quality control system of the ER.
Interestingly, at least one disease-causing mutation in the
discoidin domain (R141H) results in normal expression and
secretion from cells.15 The mechanism by which this muta-
tion causes XLRS is unknown.
Retinoschisin knockout mice exhibit many features
found in persons with XLRS.16 These include disorganiza-
tion of the retinal cell layers with gaps in the inner retina,
reduction in the b-wave amplitude of the full-field ERG,
marked decrease in the photopic response, and progressive
rod and cone photoreceptor degeneration. More recently,
retinoschisin-deficient mice have been used as a model sys-
tem to test the proof-of-principle concept that adeno-asso-
ciated viral (AAV)–mediated RS1 gene delivery can serve as
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a potential treatment for XLRS.17,18 A single subretinal in-
jection of recombinant AAV containing human RS1 cDNA
under the control of a mouse opsin promoter was shown to
result in prolonged retinoschisin expression and normal
localization in the retina. This correlated with increases in
scotopic and photopic ERGs, significant improvement in
retinal cell and synaptic organization, absence of inner ret-
ina splitting, and increased rod and cone survival.18
Although these studies suggest that delivery of the normal
RS1 gene to photoreceptors deficient in retinoschisin expres-
sion can rescue the structure and function of the retina, it
remains to be determined whether delivery of the normal RS1
gene to cells expressing mutant protein is equally effective.
Because retinoschisin is a multisubunit protein, assembly of the
normal protein subunits with mutant subunits within the cell
could result in the expression and secretion of a nonfunctional
retinoschisin complex, thereby limiting the application of gene
therapy for XLRS. In this article, we have examined the inter-
action of wild-type (WT) retinoschisin with various disease-
causing mutants to further evaluate the potential application of
gene therapy as a general treatment for XLRS.
MATERIALS AND METHODS
Generation of cDNA Constructs
Human wild-type (WT)-RS1 cDNA and C59S, R141C, C142W, and
C142S mutants in pCEP4 (Invitrogen, Carlsbad, CA) have been de-
scribed.10 Quick change site-directed mutagenesis (Stratagene, La Jolla,
CA) was used to introduce the following amino acid substitutions into
RS1 (T185K, R141H, R141G, R141A, R141K, R141E, R141Q, R141V,
R141S, D158N). The myc tag was inserted into WT-RS1 cDNA follow-
ing the leader sequence (after aa 23) by PCR amplification of RS1
fragments containing a 5 untranslated region, the N-terminal part of
RS1 from position 1 to 69 (aa 1–23), the N-terminal half of the myc tag
sequence, and an AseI restriction site using primers P1 and P3 and
amplification of a fragment consisting of an AseI site, the C-terminal
half of the myc tag and the C-terminal part of RS1 position 70 to 675
(aa 24–224), and a 3 untranslated region using primers P2 and P4.
Purified fragments were digested with AseI (New England Biolabs,
Pickering, ON, Canada) and ligated with T4 ligase (NEB). The resultant
product was reamplified by PCR and cloned in pCEP4 using XhoI and
HindIII. Primers used were as follows, with the AseI restriction site
marked in bold letters: P1, AGCAGAGCTCGTTTAGTGAACCG; P2, GT-
GGTTTGTCCAAACTCATC; P3, GAAATTAATCAGTGAGGAAGATCT-
GTCTACCGAGGATGAAGGCG; P4, CTGATTAATTTCTGCTCCGATA-
ATCCCAATGTGGCTTC. All constructs were sequenced to verify the
desired mutation and the absence of random mutations.
Cell Culture and Transfection
EBNA 293 cells (American Type Culture Collection, Manassas, VA)
were grown in Dulbecco modified Eagle medium (DMEM) with L-
glutamine, 10% fetal calf serum, and G418 (Invitrogen). Single trans-
fections were carried out in 10-cm dishes with 20 g DNA per dish
using the calcium phosphate transfection procedure previously de-
scribed.10 For cotransfection, 10 g myc-tagged RS1 (myc-RS1) and 10
g other plasmids were used. Briefly, 500 L BES-buffered saline (50
mM N,N-bis(2-hydroxyethyl)-2-aminoethane, 280 mM NaCl, 1.4 mM
Na2PO4, pH 6.95) was added dropwise to a DNA solution containing
250 mM calcium chloride and was incubated for 20 minutes at room
temperature. DNA was then added to exponentially growing EBNA 293
cells at 37°C under 5% CO2. The DNA-containing medium was replaced
with regular medium the next day, and the cells were harvested 2 days
later.
Immunoprecipitation and Protein Analysis
RS1 3R1016 and the myc 9E10 (Developmental Studies Hybridoma
Bank, Iowa City, IA) monoclonal antibodies were purified from hybrid-
oma cell supernatants by protein G affinity chromatography and cou-
pled to CNBr-activated Sepharose 2B.19 Immunoprecipitation, SDS gel
electrophoresis, and Western blotting were performed as described
previously.9,10
Immunofluorescence Microscopy
Transfected COS-7 cells were grown in DMEM with L-glutamine and
10% fetal calf serum on polylysine-coated coverslips at 37°C and fixed
with 4% paraformaldehyde in phosphate buffer (PB; 0.1 M phosphate,
pH 7.4) for 25 minutes. Coverslips were blocked in PB with 0.5%
Triton X-100 and 10% goat serum for 30 minutes and labeled overnight
with polyclonal RS1 antiserum (1:1000 dilution) or an affinity-purified
polyclonal antibody against the myc tag (1:500 dilution) and a mono-
clonal antibody against the ER marker GRP94 (1:300 dilution). After
washing with PB, the samples were labeled with goat anti–mouse
immunoglobulin conjugated with Alexa 568 and with goat anti–rabbit
immunoglobulin conjugated with Alexa 488 followed by DAPI staining.
Labeled cells were examined under a fluorescence microscope (Axio-
plan 2; Zeiss, Oberkochen, Germany) equipped with a digital image
analysis system.
RESULTS
Cellular Expression and Biochemical Analysis of
Myc-Tagged RS1
To distinguish between WT and mutant retinoschisin in coex-
pression experiments, a 9-amino acid myc epitope was in-
serted just downstream of the N-terminal leader peptide cleav-
age site (Fig. 1). The effect of the myc tag on the subcellular
localization of retinoschisin was examined in transfected
COS-7 cells by immunofluorescence microscopy. Figure 2A
shows that myc-tagged retinoschisin (myc-RS1), like the un-
tagged WT retinoschisin protein (WT-RS1), had a perinuclear
pattern that colocalized with the GRP-94 ER marker.
Next, we determined whether myc-RS1 is secreted from
cells as a disulfide-linked oligomeric complex similar to
WT-RS1. Figure 2B shows that myc-RS1 was present in the
secreted fraction of transfected cells at levels comparable to
FIGURE 1. Schematic of retinoschi-
sin showing the location of the signal
or leader sequence (LS; amino acids
1–23), Rs1 domain (Rs1; amino acids
24–62), discoidin domain (amino ac-
ids 63–219), and the carboxyl termi-
nal (CT) segment (amino acids 220–
224). The location of the 9-amino
acid myc-tag (EQKLISEED) and the
disease-causing missense mutation
studied are shown.
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those of WT-RS1 and that it migrated on SDS gels as a 24-kDa
monomer under disulfide-reducing conditions and a 180-kDa
oligomer characteristic of an octamer under nonreducing
conditions.9 The decreased mobility of myc-RS1 relative to
WT-RS1 is consistent with its increased size because of the
myc epitope.
Expression of WT and Disease-Linked Mutants
The expression of WT-RS1 and a number of disease-linked
mutants was examined in the cellular and secreted fractions
of transfected cells. All mutants were detected in the cellular
fraction of EBNA 293 cells at levels comparable to that of
WT RS1; however, only the C59S and R141H mutants were
observed in the secreted fractions (Fig. 3). The R141H mu-
tant, like WT-RS1, assembled into a disulfide-linked oc-
tameric complex (see Fig. 7), whereas the C59S mutant did
not, as previously reported.10,15 R141G, C142W, C142S, and
T185K mutants were not present in the secreted fraction,
indicating that these proteins were highly misfolded and
were retained inside the cells by the quality control system
of the ER.
Coexpression and Interaction of Myc-RS1
with WT-RS1
To determine whether myc-tagged RS1 associates with the
WT protein to form a nativelike complex, the secreted
fraction from cells coexpressing the myc-RS1 and WT-RS1
was compared with the secreted fractions from individually
transfected cells under nonreducing conditions. As shown
in Figure 4, a mixture of individually expressed myc-RS1 and
WT-RS1 (lane b) resolved into two closely spaced bands
corresponding to myc-RS1 (upper band) and WT RS1 (lower
band). In contrast, the coexpression of myc-RS1 and WT-RS1
resulted in a broader band (lane c) that migrated between
the WT RS1 (lane a) and myc-RS1 band (lane d). This sug-
gests that disulfide-linked octameric complexes consisting
FIGURE 2. Immunofluorescence and
Western blotting of WT-RS1 and myc-
RS1. (A) Immunofluorescence micros-
copy of COS-7 cells expressing WT-
RS1 or myc-RS1. Cells were double
labeled with a polyclonal antibody to
RS1 (pAbRS1) or a polyclonal antibody
to the myc tag (anti-myc) and a mono-
clonal antibody to the ER marker
GRP94 (anti-GRP94) followed by goat
anti–rabbit immunoglobulin Alexa 488
(green) and goat anti–mouse immuno-
globulin Alexa 568 (red) and subse-
quently stained with the nuclear dye
DAPI. Merged images are also shown.
(B) Western blot analysis of the se-
creted fraction from cells expressing
WT-RS1 and myc-RS1 under disulfide-
reducing and -nonreducing conditions.
Blots were labeled with the RS1 3R10
monoclonal antibody.
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of the myc-RS1 and WT RS1 proteins form when these
proteins are coexpressed and secreted from cells.
Coexpression of Myc-RS1 with
Disease-Linked Mutants
The interaction between myc-RS1 and disease-linked RS1 mu-
tants was studied in coexpression and coimmunoprecipitation
experiments. First, the ability of RS1 mutants to coexpress with
myc-RS1 was examined. Figure 5 shows that the cellular frac-
tion of cotransfected cells contained two closely spaced bands
under disulfide-reducing conditions corresponding to myc-RS1
(upper band) and untagged WT or mutant RS1 (lower band).
To determine whether myc-RS1 associates with mutant pro-
teins to form a complex that is secreted from cells, coimmu-
noprecipitation experiments were carried out. The secreted
fraction from cells coexpressing myc-RS1 and WT or mutant
RS1 was immunoprecipitated on either the anti–RS1 3R10-
Sepharose or the anti–myc 9E10-Sepharose matrix, and the
bound fraction was analyzed on Western blot analysis labeled
with the anti–RS1 antibody, which recognizes both myc-RS1
and untagged RS1, or the anti–myc antibody, which recognizes
only myc-RS1. The presence of two anti–RS1-labeled bands in
the bound fraction of RS1 3R10-Sepharose indicates that the
untagged WT or mutant RS1 (lower band) is present in the
secreted fraction together with myc-RS1 (upper band),
whereas two bands from myc 9E10-Sepharose show that a
complex was formed between myc-RS1 and WT or mutant RS1.
The results of these studies are shown in Figure 6A and
Table 1.13–15,20–23 Immunoprecipitation with RS1 3R10-Sepha-
rose showed two bands in the secreted fraction from cells
expressing myc-RS1 with WT-RS1, the polymorphic D158N
variant, and the disease-causing mutants, C59S and R141H, but
only a single myc-RS1 band for coexpression with the R141G,
C142W, C142S, and T185K mutants, indicating that WT,
D158N, C59S, and R141H proteins are present with myc-RS1 in
the secreted fraction, whereas the R141G, C142W, C142S, and
T185K mutants are retained inside the cell when expressed
individually or with myc-RS1. Immunoprecipitation with myc
FIGURE 3. Expression of WT RS1,
myc-RS1, and disease-causing RS1
mutants. Cellular and secreted frac-
tions of individually transfected
EBNA 293 cells were run on 10%
reducing gels. Western blots were la-
beled with RS1 3R10 monoclonal an-
tibody.
FIGURE 4. Western blot analysis of the secreted fraction from cells
individually expressing WT-RS1 and myc-RS1 and coexpressing these
proteins. Lane a: secreted fraction from cells expressing only WT-RS1.
Lane b: mixture of secreted fraction of cells individually expressing
WT-RS1 and myc-RS1. Lane c: secreted fraction from cells coexpress-
ing WT-RS1 and myc-RS1. Lane d: secreted fraction from cells express-
ing only myc-RS1. SDS gels were run under nonreducing conditions,
and Western blots were labeled with the RS1 3R10 monoclonal anti-
body.
FIGURE 5. Western blot analysis of the cellular fraction from cells
coexpressing myc-RS1 with WT-RS1 or RS1 mutants. Western blots
were labeled with the RS1 3R10 monoclonal antibody. The upper
band represents myc-RS1, and the lower band represents WT or
mutant RS1.
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9E10-Sepharose showed the presence of two bands for the WT,
D158N variant, and R141H mutant but only a single band for
C59S mutant, indicating that WT, D158N, and R141H associate
with myc-RS1 to form a complex, whereas the C59S mutant
does not assemble with myc-RS1. Western blot analysis labeled
with an anti–myc antibody showed the presence of myc-RS1 in
the secreted fractions of all mutants (Fig. 6B).
Expression, Oligomerization, and Secretion of
RS1 Mutants with Various Amino Acid
Substitutions at Position 141
The R141H mutant is unique among the disease mutants stud-
ied here in that, like WT-RS1, it is secreted from cells as a
disulfide-linked octameric complex and is capable of interact-
ing with WT-RS1 to form a nativelike complex. It was of
interest to determine what effect replacement of arginine at
position 141 with other amino acids has on protein expression,
oligomerization, and secretion. As shown in Figure 7, all RS1
141 mutants studied were expressed at levels similar to those
of WT-RS1, as analyzed for the cellular fraction. However, only
three mutants, R141H, R141A, and R141S, were secreted from
cells as octamers at levels similar to those of WT-RS1.
DISCUSSION
In previous studies, transfected EBNA 293 and COS-7 cells
were used to study the expression, secretion, and subunit
assembly of WT and disease-causing retinoschisin mu-
tants.9,10,14,15 Most mutations in the discoidin domain resulted
in protein misfolding, aggregation, and complete retention in
cells by the quality control system of the ER (Table 1). A few
proteins with disease-causing mutations in the discoidin do-
FIGURE 6. Coexpression and coim-
munoprecipitation of myc-RS1 with
WT-RS1 or mutant RS1. Secreted frac-
tions from cells coexpressing myc-
RS1 and WT-RS1 or mutant RS1 were
coimmunoprecipitated with anti–
RS1 (3R10) or with anti–myc (9E10)
Sepharose. Bound proteins were run
on a 15% SDS-polyacrylamide gels un-
der reducing conditions, and West-
ern blots were labeled with the RS1
3R10 monoclonal antibody (A) or a
polyclonal antibody to the myc
epitope (B).








WT Yes Yes Yes No —
C59S Yes Yes No Yes13,14 No
R141G Yes No* No Yes13,15,20 No
R141H Yes Yes Yes Yes13,21 Yes
R141A Yes Yes Yes NR ND
R141V Yes No No NR ND
R141S Yes Yes Yes NR ND
R141Q Yes No No NR ND
R141C Yes No No Yes13,20 ND
R141E Yes No No NR ND
R141K Yes No No NR ND
C142W Yes No No Yes15,22 No
C142S Yes No No NR No
D158N Yes Yes Yes No13 Yes
T185K Yes No No Yes23 No
*Wang et al.14 reported the secretion for the R141G mutant from COS-7 cells but at low levels. NR,
none reported to date; ND, not determined.
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main were reported to be secreted from cells, but at a signifi-
cantly reduced level.15 In such cases, a small fraction of the
proteins apparently adopt a conformation sufficiently similar to
that of the WT protein to pass through the ER quality control
system as part of the secretion process.
The R141H disease-linked mutant, as recently reported by
Wang et al.15 and confirmed in this report, is unique among the
disease-causing mutations studied to date. Like WT retinoschi-
sin, this mutant is expressed and secreted at normal levels as an
octamer, suggesting that this protein preferentially folds into a
nativelike conformation. The fact that this mutant causes
XLRS,21 however, suggests that it may be defective in its
function as an extracellular retinal protein. The C59S and
C223R disease-causing mutations just outside the discoidin
domain result in proteins that are also secreted from cells at
essentially normal levels, but they are defective in their ability
to form disulfide-linked octamers characteristic of WT retinos-
chisin, indicating that the octameric structure is required for
retinoschisin function.9,10
Despite the different effect various disease mutations, in-
cluding R141H, have on the structure and secretion of retinos-
chisin, to date no significant correlation has been found be-
tween the severity of the disease phenotype and the
underlying genotype.20,21
The main objective of this study was to determine whether
WT RS1 can assemble with various disease-causing mutants and
promote secretion of the mixed mutant proteins from cells.
Normally, X-linked alleles are expressed in different cells be-
cause of X-linked gene inactivation. As a result, female carriers
of XLRS express the WT gene in one cell and the mutated gene
in another cell. Hence, the WT and mutant proteins do not
have an opportunity to coassemble as a complex during pro-
tein synthesis and secretion. Indeed, in most instances, only
the WT protein is secreted from cells because most disease-
causing missense mutations result in protein misfolding and
retention inside the cell, as discussed. Female carriers of XLRS
studied to date do not exhibit the disease phenotype because
sufficient WT protein is produced and secreted from cells
expressing the normal gene. However, therapeutic gene deliv-
ery can, in principle, present a problem. The introduction of
the normal RS1 gene into cells expressing a mutated gene
could result in the formation of a mixed complex that, even if
secreted, could prove nonfunctional. This would nullify the
benefits of gene therapy as a treatment for XLRS. Therefore, it
is important to determine whether WT retinoschisin interacts
with mutant retinoschisin when expressed in the same cell
and, if so, what effect this has on protein oligomerization,
secretion, and ultimately function.
To distinguish between WT and mutant retinoschisin, we
introduced a myc epitope immediately downstream of the
signal peptidase cleavage site. The myc-RS1 showed properties
similar to those of WT RS1 with regard to its level of expres-
sion, distribution within cells, and secretion as a disulfide-
linked octamer. Myc-RS1 could be readily distinguished from
WT or mutant RS1 on the basis of its small increase in size and
its recognition by anti–myc antibodies. Importantly, coexpres-
sion of myc-RS1 with WT RS1 or RS1 containing the D158N
polymorphism further showed that myc-RS1 could assemble
with these proteins to form mixed octameric complexes that
were efficiently secreted from cells.
The interaction of normal RS1 (myc-RS1) with selected
disease-causing mutants was investigated using coexpression
and coimmunoprecipitation. All mutants coexpressed with
myc-RS1 in cells. However, though the myc-RS1 was secreted
from cells, all discoidin domain mutants, with the exception of
the R141H mutant, were retained inside cells. This indicates
that the WT retinoschisin folded and assembled into a disulfide-
linked octamer independent of the mutant misfolded proteins
and was effectively secreted from cells. In contrast, the R141H
mutant assembled with WT-RS1 and was secreted as a mixed
octameric complex. Thus, the R141H is similar to WT retinos-
chisin not only in its ability to be secreted from cells as an
octamer but also in its ability to interact with the WT subunits.
When the C59S octamer-defective mutant was cotransfected
with myc-RS1, these proteins did not associate with each other,
though they were secreted from cells. Previous studies indicate
the C59S mutant can form C40-mediated disulfide-linked
dimers but not octamers.9,10 The fact that C59S-myc-RS1
dimers were not observed in coimmunoprecipitation studies
suggests that the presence of the myc tag within the Rs1
domain may impede heterodimer formation.
Our studies indicate that the introduction of the normal RS1
gene into cells expressing disease-causing mutants should not
pose a problem in gene delivery studies because the normal
retinoschisin protein expresses, assembles, and is secreted
independently of the mutant RS1. The R141H mutant, how-
ever, is a possible exception because it assembles with WT-
RS1. The function of RS1 or its interaction with other cell
components is unknown at present. When these properties are
known, it will be important to determine whether the oc-
tameric complex consisting of R141H, alone or with WT-RS1,
is fully or at least partially functional.
FIGURE 7. Expression and secretion
of WT RS1 and R141 RS1 mutants.
Cellular and secreted fractions from
individually transfected EBNA 293
cells were analyzed under reducing
or nonreducing conditions on West-
ern blots labeled with the RS1 3R10
monoclonal antibody. All proteins
expressed were detected as 24-kDa
monomeric proteins in the cellular
fraction under reducing conditions,
but only WT RS1 and the R141H,
R141A, and R141S mutants were de-
tected in the secreted fraction as
monomers under reducing condi-
tions and octamers under nonreduc-
ing conditions.
2496 Dyka and Molday IOVS, June 2007, Vol. 48, No. 6
Downloaded from iovs.arvojournals.org on 07/02/2019
Although the R141H mutant exhibits structural properties
similar to those of WT-RS1, the R141G disease-causing mutant
does not. Wang et al.14 reported that R141G is secreted from
COS-7 cells, though at reduced levels compared with R141H
and WT proteins. We were unable to detect the R141G mutant
in the secreted fraction from transfected EBNA 293 cells. It is
possible that the differences in chaperone proteins in COS-7
and EBNA 293 cells account for the variation in R141G secre-
tion from these cells. The differences in behavior of the R141H
and R141G mutants first suggested to us that positively charged
or polar residues may be required at codon 141 for effective
folding and secretion of the retinoschisin protein. Therefore,
we examined a number of mutants with different amino acid
substitutions. In our cell system, only R141S, R141A, and
R141H mutants were efficiently secreted from cells. These
results indicate that an amino acid residue with a positively
charged or even a polar residue at codon 141 is not required
for effective folding, octamerization, or secretion of retinoschi-
sin. Amino acid residues with small side chains, such as serine
and alanine, appear to allow proper folding and octameriza-
tion. A high-resolution structure of retinoschisin is not available
at present. Examination of a model of the retinoschisin discoi-
din domain derived from factor 5 and factor 810 suggests that
arginine residue 141 is highly inaccessible to solvent and there-
fore likely plays a role in protein folding.
In summary, our studies indicate that WT-RS1 undergoes
protein folding, oligomerization, and secretion independently
of disease-causing misfolded RS1 mutants. Therefore, with the
exception of R141H, delivery and expression of WT-RS1 into
cells expressing disease-causing RS1 missense mutants should
not be detrimental to patients with XLRS. However, it is pos-
sible that photoreceptors may process proteins differently than
do the EBNA 293 cells used in this study. Therefore, it would
be advisable to determine whether WT-RS1 expressed in pho-
toreceptor cells of mice harboring disease-causing RS1 mis-
sense mutations results in the recovery of retinal structure and
function before gene therapy trials.
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